Key Highlights
- Shares are trading at $58.00 in pre-market activity, up 5.61% from Monday's close of $54.92.
- The company posted second-quarter Revenue of $27.5 million, beating estimates by roughly 27%, and swung to a net profit of $177.3 million, aided by a $181.5 million tax benefit.
- Global Jemperli net sales grew 34% year over year to $644 million for the first half of 2026.
- The FDA has assigned a February 2027 PDUFA date for Jemperli in rectal cancer, with a pending December 2026 decision for Quimilza in generalized pustular psoriasis.
Strong Earnings Report Drives Shares Higher
AnaptysBio (NASDAQ:ANAB) shares rose in pre-market trading Tuesday as investors responded positively to a strong second-quarter fiscal 2026 earnings report released after Monday's close. The report reflected a streamlined, royalty-focused Business following the April 2026 spin-off of First Tracks Biotherapeutics. AnaptysBio manages the financial collaborations for Jemperli with GSK (NYSE:GSK) and Quimilza with Vanda Pharmaceuticals (NASDAQ:VNDA), focused on protecting and returning the value of its royalties to shareholders.
The company posted revenue of $27.5 million, beating estimates by roughly 27%, and swung to a large net profit of $177.3 million, aided by a $181.5 million tax benefit tied to the release of a valuation allowance on deferred tax assets.
Jemperli Sales Growth and Regulatory Progress Reinforce Sentiment
Investors are also encouraged by continued strong sales growth for Jemperli, which grew 34% year over year to $644 million globally for the first half of 2026, along with positive interim results from the AZUR-1 trial and an FDA PDUFA action date of February 2027 for Jemperli in rectal cancer. A pending December 2026 FDA decision for Quimilza in generalized pustular psoriasis adds a second near-term regulatory catalyst.
GSK Litigation Remains a Key Overhang
The ongoing litigation with GSK and Tesaro over Jemperli rights remains a key overhang on the stock, with a post-trial hearing scheduled for October 20, 2026, and a judgment anticipated in the fourth quarter of 2026 or first quarter of 2027.
Litigation Outcome and Regulatory Decisions Are the Next Catalysts
AnaptysBio shares are climbing as strong Jemperli growth and regulatory progress outweigh the litigation overhang for now. The upcoming litigation judgment, alongside the Quimilza and Jemperli regulatory decisions, will likely shape the stock's next move.






Please wait processing your request...